In this episode of The Promise of Personalized Medicine, Perry sits down Eugean Jimanwall, Senior Research Analyst for Medical Policy & Technology Evaluation at Independence Blue Cross’ Medical & Claim Payment Policy Department within Facilitated Health Networks and Medical Affairs.

He is a seasoned expert with more than 15 years of experience in medical policy and health technology assessment. Together, they unpack the evolving world of personalized and precision medicine—what it really means, why the concept isn’t new, and how modern tools like next-generation sequencing and biomarkers are advancing accuracy in care.

Eugene shares insights about:

• Reviewing evidence for medical policy, highlighting both the opportunities and common challenges companies face when validating new tests 
• The importance of clinical utility data to the role of biomarkers in shaping treatment decisions
• The necessity of aligning evidence generation (validity, utility, etc.) with what payors, policy bodies, or HTA organizations require
• Need for clinically meaningful improvements, not just statistical significance. What matters in practice (improved management, symptom relief, survival, quality of life).
• While personalized medicine is about the individual, policy / reimbursement / HTA often think in terms of subpopulations (e.g. groups with a biomarker) or larger cohorts.

This episode offers a candid, expert perspective on what it takes to move from theory to meaningful outcomes.

—-------

Stay connected with our host, Perry Dimas, here on LinkedIn!
📧 Interested in joining our medical director advisory group? Email us at [email protected]
🔗 Connect on LinkedIn: linkedin.com/company/accessdx